RMD Open

Effect of targeted therapies on pulmonary function in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

Introduction Interstitial lung disease (ILD) is a serious extra-articular manifestation of rheumatoid arthritis (RA) ...
RMD Open

Cellular and molecular basis of neuropathic pain

Neuropathic pain is a devastating type of pain that significantly reduces the quality of life of affected people.
RMD Open

Autoantibody biomarkers and first-line therapy response in RA: findings from the CAP48 cohort

Objective A panel of antibodies against three antigens, University Hasselt (UH)-rheumatoid arthritis (RA).305, 318 and 329, ...
rmdopen.bmj

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Objective Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using ...
rmdopen.bmj

Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift

Treatment of rheumatoid arthritis (RA) has improved substantially during the last decades, mainly due to the development and introduction in everyday practice of new, highly efficacious, ...
rmdopen.bmj

Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a ...

Objective Proactive therapeutic drug monitoring (pTDM) intends to optimise tumour necrosis factor (TNF) inhibitor treatment through regular assessment of drug and antidrug antibody levels, enabling ...
rmdopen.bmj

The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in ...

Objectives To evaluate the safety, efficacy and response duration of four different dosing regimens of dazodalibep (DAZ), a non-antibody biological antagonist of CD40L, in patients with rheumatoid ...
rmdopen.bmj

Longitudinal association of early axial spondyloarthritis status at the time of diagnosis with disease activity over time: 10-year results from the GESPIC cohort

Objective Recently, the definition for ‘early axial spondyloarthritis (axSpA)’ was developed by the Assessment of SpondyloArthritis international Society (ASAS), including ≤2 years of axial symptoms ...
rmdopen.bmj

Discrepancies between routine sacroiliac joint MRI reporting and current expert recommendations in patients with spondyloarthritis

Background Sacroiliac joint (SIJ) MRI is commonly used in diagnosing spondyloarthritis (SpA). Current Assessment of SpondyloArthritis International Society (ASAS) recommendations on reporting SIJ MRIs ...
rmdopen.bmj

Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis

Objectives This study aimed to evaluate the risk of tuberculosis associated with the use of Janus kinase (JAK) inhibitors or biological disease-modifying antirheumatic drugs (bDMARDs) in patients ...
rmdopen.bmj

Trajectories of self-reported pain-related health outcomes and longitudinal effects on medication use in rheumatoid arthritis: a prospective cohort analysis using the ...

Objective To determine distinct trajectories of self-reported pain-related health status in rheumatoid arthritis (RA), their relationship with sociodemographic factors and medication use. Methods 988 ...
rmdopen.bmj

Association between SARC-F as a self-report screening tool for sarcopenia and muscle strength, physical performance, daily activity, patient-reported outcomes and body ...

Background This study aimed to explore the association of the sarcopenia questionnaire Strength, Assistance with walking, Rise from a chair, Climb stairs, Falls (SARC-F) with muscle strength, physical ...